Pharma BD Deal Intelligence
Zerbaxa (ceftolozane/tazobactam) reached the market but never delivered — a $402.5M deal for Cubist that produced modest sales before a 2020 sterility recall forced a $1.6B impairment charge for eventual owner Merck. The antibiotic got approved and expanded to pneumonia, though it never became the leader Cubist envisioned.
Calixa's antibiotic became Zerbaxa and got FDA-approved, but it never became the "market leader" Cubist hoped for — and a 2020 sterility recall triggered a $1.6B impairment for eventual owner Merck.
Full analysis, sources & comparables →Cubist to acquire Calixa for $92.5M cash upfront plus up to $310M in development, regulatory and commercial milestones; CXA-201 combines novel anti-pseudomonal…
Zerbaxa received FDA approval December 2014 for cUTI and cIAI, with later HABP/VABP expansion; demonstrated potency against multidrug-resistant Pseudomonas…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$92.5M upfront cash + up to $310M milestones. CXA-101 (ceftolozane/tazobactam, Zerbaxa) anti-infective. Source: Fierce Biotech, Cubist 10-K.
Calixa's antibiotic became Zerbaxa and got FDA-approved, but it never became the "market leader" Cubist hoped for — and a 2020 sterility recall triggered a $1.6B impairment for eventual owner Merck.
Assessment window: 15yr post-close.
2.8M US cases/yr · $6.0B US annual cost burden of cUTI (>$6B)
Complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by multidrug-resistant Gram-negative pathogens — particularly Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae — represent a high-mortality, high-cost hospital problem. Existing carbapenems were facing rising resistance, and the antibiotic pipeline was thin, creating urgent need for new anti-pseudomonal agents.
At deal time (December 2009), the IV anti-pseudomonal cephalosporin landscape was dominated by ceftazidime and cefepime, with carbapenems (meropenem, imipenem, doripenem/Doribax — Shionogi/Janssen) and piperacillin/tazobactam (Zosyn — Wyeth/Pfizer) covering broader Gram-negative therapy. Resistance to all of these was rising rapidly, especially in Pseudomonas. CXA-101 (later ceftolozane) was differentiated as a novel anti-pseudomonal cephalosporin with retained activity against ceftazidime-resistant P. aeruginosa, paired with the established β-lactamase inhibitor tazobactam to expand ESBL coverage. The deal was strategically critical for Cubist because Cubicin (daptomycin) — its Gram-positive franchise — was on a finite patent runway, and Cubist needed a Gram-negative asset to anchor its anti-infective platform. The bet paid off: ceftolozane/tazobactam was approved by FDA as Zerbaxa in December 2014 for cUTI and cIAI, then expanded to HABP/VABP, and was a meaningful asset in Merck's $9.5B acquisition of Cubist in 2015.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cubist Pharmaceuticals, Inc. / Calixa Therapeutics, Inc. (this deal) | 2009 | $402M | 52 |
| Cubist Pharmaceuticals, Inc. / Adolor Corporation | 2011 | $415M | 49 |
| Cubist Pharmaceuticals, Inc. / Optimer Pharmaceuticals, Inc. | 2013 | $801M | 45 |
| Cubist Pharmaceuticals, Inc. / Trius Therapeutics Inc. | 2013 | $707M | 44 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |